Skip to main content

Table 3 Sample characteristics, PLHIV

From: Objective impairments of gait and balance in adults living with HIV-1 infection: a systematic review and meta-analysis of observational studies

Study ID Disease staging CD4 cell count, cells/mm3 (SD) Viral load (SD) Treatment
Trenkwalder 1992 [46] WR I-II (N = 17); WR III-V (N = 19); WR VI (N = 14) NR NR NR
Arendt 1994 [47] CDC II (N = 12); CDC III (N = 12); CDC IV C1 (N = 5); CDC IV C2 (N = 5); CDC IV D (N = 2); CDC IV B (N = 10) NR NR NR
Beckley 1998 [50] ASX (N = 2); CDC Stage A (N = 2); CDC Stage B (N = 2); CDC Stage C (N = 3) Range 65–701; 5 participants had AIDS-defining CD4 counts (<200) NR Most were on zidovudine maintenance therapy
Bauer 2005 [7] NR NRx: 351 (282); NNRTI: 457 (375); PI: 320 (200) HIV burden × 1000 copies/ml: NRx: 93.8 (163); NNRTI: 35.5 (102); PI: 20.1 (48.2) NRx: N = 28; NNRTI: N = 25; PI: N = 37
Simmonds 2005 [49] Based on CD4 count
ASX (CD4 > 200) (N = 52); AIDS (CD4 < 200) (N = 48)
Range 189.83 (183.27) - 386.36 (302.39) Virions:
ASX 33545.25; AIDS 193401.00
NR
Dellepiane 2005 [48] CDC classificationASX (N = 15); AIDS (group IV) (N = 15) NR NR NR
Scott 2007 [35] NR 408 (293) log copies/ml
2.18 (0.94)
All were on a NRTI-based regimen, with 82% receiving a PI as a third agent
Richert 2011 [8] CDC category C: 23% a520 (348, 709) <500 copies/ml: 83% 89%
Bauer 2011 [22] NR BMI <21: 280 (52); BMI 21–29: 422 (40); BMI > 29: 361 (64) Log10 viral load
BMI <21: 3.06 (0.34); BMI 21–29: 2.19 (0.26); BMI > 29: 2.08 (0.39)
% no ART/NNRTI-based ART/ PI-based ART: BMI <21: 38.2/26.5/35.3; BMI 21–29: 31.7/26.7/
41.7; BMI > 29: 37.0/18.5/44.4
Sullivan 2011 [21] NR M 537.4 (258.97); F 583.4 (103.55) M 13597.6 (4654.88); F 4609.7 (3226.36) HAART: N = 25; Non-HAART: N = 6; NRx: N = 9
Erlandson 2012a [10] NR a551 (361, 768) Detectable (≥48 copies/mL): 5% NR
Erlandson 2012b [18] NR 594 (16) 95% had plasma HIV-1 RNA < limits of detection Any didanosine: Non-fallers: 57 (23); Single fallers: 10 (23); Recurrent fallers: 24 (36) Any stavudine: Non-fallers: 93 (37); Single fallers: 22 (51); Recurrent fallers: 33 (50) Efavirenz: Non-fallers: 86 (34); Single fallers: 10 (23); Recurrent fallers: 22 (33)
Cohen 2012 [45] NR 556.4 (284) Log 10 HIV RNA:
a3.50 (2.68, 4.42)
HAART: 76.9%
Beans 2013 [43] NR a445 (265, 531) Non-detectable (<400 copies/ml): 91% Majority were receiving cART
Mbada 2013 [44] All: Clinical stage I of HIV/AIDS (ASX HIV infection, with PGL) NR NR 100% HAART
Richert 2014 [9] CDC stage C 24% a506 (340, 715) HIV RNA level < 500 copies/ml: 84% 89% on ART
Erlandson 2014 [12] NR 594 (303) HIV-1 RNA < limits of detection: 95% All participants taking effective cART
  1. Abbreviations: AIDS acquired immunodeficiency syndrome, ART antiretroviral therapy, ASX asymptomatic, BMI Body Mass Index, cART combination antiretroviral therapy, CDC Centre for Disease Control, F female, HAART highly active antiretroviral therapy, HIV human immunodeficiency virus, IQR interquartile range, M male, N number of participants, NA not applicable, NNRTI non-nucleoside reverse transcriptase inhibitor, NR not reported, NRTI nucleoside reverse transcriptase inhibitors, NRx no treatment, PGL Persistent generalized lymphadenopathy, PI protease inhibitor, PLHIV people living with HI, SD standard deviation, SX symptomatic, WR Walter Reed staging
  2. aMedian (IQR)